ImmunoGen price outlook as shares spike 30% on positive mirvetuximab data
On Tuesday, ImmunoGen Inc. (NASDAQ:IMGN) shares surged by nearly 30% after reporting positive mirvetuximab data in ovarian cancer. The company announced positive top-line data from the SORAYA trial, which measured the safety and efficacy of mirvetuximab soravtansine. However, ImmunoGen shares eased later in the after-hours session, losing more than 4% after the company announced $175
The post ImmunoGen price outlook as shares spike 30% on positive mirvetuximab data appeared first on Invezz.